Beijing Beilu Pharmaceutical (300016) — Tangible Net Worth Ratio
Beijing Beilu Pharmaceutical (300016) has a Tangible Net Worth Ratio of 93.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥152.07 Million) from net assets (CN¥2.37 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See what is Beijing Beilu Pharmaceutical's book value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Beijing Beilu Pharmaceutical Tangible Net Worth Ratio (2005–2024)
This chart shows how Beijing Beilu Pharmaceutical's Tangible Net Worth Ratio has changed across 20 annual periods from 2005 to 2024. As of September 2025, the ratio stands at 93.6%, reflecting net assets of CN¥2.37 Billion with intangible assets of CN¥152.07 Million CNY. Also explore Beijing Beilu Pharmaceutical equity growth rate to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Beijing Beilu Pharmaceutical (2005–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Beijing Beilu Pharmaceutical from 2005 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market cap of Beijing Beilu Pharmaceutical.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 91.2% | CN¥1.83 Billion | CN¥160.82 Million | CN¥2.98 Billion | ▼ -1.6 pp |
| 2023 | 92.8% | CN¥1.79 Billion | CN¥128.39 Million | CN¥2.82 Billion | ▲ +0.5 pp |
| 2022 | 92.3% | CN¥1.92 Billion | CN¥147.26 Million | CN¥2.82 Billion | ▲ +0.0 pp |
| 2021 | 92.3% | CN¥2.08 Billion | CN¥160.39 Million | CN¥2.90 Billion | ▲ +1.1 pp |
| 2020 | 91.2% | CN¥1.89 Billion | CN¥167.07 Million | CN¥2.85 Billion | ▼ -4.9 pp |
| 2019 | 96.0% | CN¥1.45 Billion | CN¥57.71 Million | CN¥1.62 Billion | ▲ +0.1 pp |
| 2018 | 95.9% | CN¥1.21 Billion | CN¥49.69 Million | CN¥1.29 Billion | ▲ +0.9 pp |
| 2017 | 95.0% | CN¥1.07 Billion | CN¥53.26 Million | CN¥1.14 Billion | ▼ -0.2 pp |
| 2016 | 95.2% | CN¥901.69 Million | CN¥43.47 Million | CN¥956.09 Million | ▲ +0.7 pp |
| 2015 | 94.4% | CN¥932.63 Million | CN¥51.83 Million | CN¥1.05 Billion | ▲ +0.8 pp |
| 2014 | 93.7% | CN¥666.33 Million | CN¥42.07 Million | CN¥907.00 Million | ▼ -3.4 pp |
| 2013 | 97.1% | CN¥559.38 Million | CN¥16.05 Million | CN¥620.54 Million | ▼ -0.8 pp |
| 2012 | 98.0% | CN¥523.96 Million | CN¥10.70 Million | CN¥583.60 Million | ▼ -1.1 pp |
| 2011 | 99.1% | CN¥491.47 Million | CN¥4.54 Million | CN¥524.66 Million | ▲ +0.1 pp |
| 2010 | 99.0% | CN¥467.62 Million | CN¥4.60 Million | CN¥475.11 Million | ▼ -0.1 pp |
| 2009 | 99.1% | CN¥433.71 Million | CN¥3.90 Million | CN¥451.31 Million | ▲ +2.4 pp |
| 2008 | 96.7% | CN¥133.23 Million | CN¥4.40 Million | CN¥159.75 Million | ▲ +2.6 pp |
| 2007 | 94.0% | CN¥90.33 Million | CN¥5.38 Million | CN¥141.69 Million | ▼ -0.4 pp |
| 2006 | 94.5% | CN¥71.59 Million | CN¥3.95 Million | CN¥125.69 Million | ▲ +1.8 pp |
| 2005 | 92.7% | CN¥64.71 Million | CN¥4.72 Million | CN¥107.46 Million | — |